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Abstract A new method for the selective determination of
laminin-5 concentration using a biosensor and surface plas-
mon resonance imaging (SPRI) technique is presented. A bio-
sensor based on the specific interaction of laminin-5 with rab-
bit polyclonal antibody was constructed. The analytically use-
ful dynamic response range of the biosensor is between 0.014
and 0.1 ng mL−1. The detection limit is 4 pg mL−1. The po-
tential influence of interferences on the SPRI signal was in-
vestigated, and the high selectivity of the biosensor was con-
firmed. In order to demonstrate the potential application of the
biosensor, laminin-5 concentration in blood plasma was deter-
mined. The results were compared with the laminin-5 concen-
tration obtained by the commercial enzyme-linked immuno-
sorbent assay (ELISA) kit. A comparison of results from
healthy donors obtained by SPRI measurement and ELISA
indicates that they are close and shows good agreement with
the data reported in the literature. The plasma samples of blad-
der cancer patients gave higher concentration measured with
specific biosensor than by ELISA assay. The study shows the
clear difference in concentration of laminin-5 in healthy
humans and patients with bladder cancer. Extensive clinical
studies using the newly developed method can result in an
increase in the use of laminin-5 as a potential cancer marker.
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Introduction
Surface plasmon resonance imaging (SPRI) is a tool to mon-
itor biomolecular interactions. It is a label-free optical detec-
tion technique and allows real-time monitoring of reaction
between biomolecules. The combination of SPRI technique
with the biosensors is at the forefront of analytical methods
of multi-analyte measurements [1]. This method measures the
changes of refractive index caused by molecules bound to the
metal surface. Surface plasmon resonance (SPR) is generated
at a thin metal surface when surface plasmons are excited by
the light beam at an appropriate incident angle. This angle
strongly depends on the refractive index of the dielectric ma-
terial at the interface. When the analyte binds the ligand on the
metal film, the interfacial architecture changes. The SPRI sig-
nal is dependent on the change in the wavelength and the
angle of polarization of light. It is also directly proportional
to the mass change on the surface of the metal [2]. The bio-
sensor is usually gold-coated glass with a layer of active bio-
molecule as a receptor for a determined compound. They are
based on very specific interactions between enzyme and in-
hibitor or between antigen and antibody. This allows deter-
mining the concentration of the analyte directly in the sample
[3]. SPR imaging biosensors have been increasingly applied
in medical diagnosis in which rapid and sensitive methods are
required for the determination of substances (presence and/or
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amount) that are potential markers of disease and especially
cancer markers [4–8].
Recent progress in science has highlighted the importance
of extracellular matrix (ECM) in regulation of cellular behav-
ior and major developmental processes during cancer progres-
sion. Understanding how ECM composition and its deregula-
tion influence the development and progression of diseases
may help in an early cancer diagnosis.
The extracellular matrix is a complex network of molecules
secreted by cells. They are divided into four main groups of
proteins: collagens, elastins, structural glycoproteins, and pro-
teoglycans. Glycosaminoglycans and other polysaccharides
are also involved in its maintenance. The ECMprovides struc-
tural and biochemical support of the surrounding cells. ECM
is involved in signal transduction between cells, maintaining
their shape, and also in the processes of migration and cell
growth [9, 10]. In particular, the laminins, a family of extra-
cellular glycoproteins, play an important role in ECM func-
tioning. They are a component of the basement membrane
(BM), a specialized form of extracellular matrix, in almost
all animal tissues. Laminin molecule is a heterotrimer assem-
bled from α, β, and γ chain subunits. It forms a cross shape
with one long arm and three short arms. There are five laminin
α chains (α1–α5), four laminin β chains (β1–β4), and three
laminin γ chains (γ1–γ3), and each chain type represents a
different subfamily of laminins. Currently, there are over 18
laminin isoforms [11].
Laminin-5 (Lm-332, 400 kDa) is the isoform that contains
alpha-3, beta-3, and gamma-2 chains, and it is expressed pre-
dominantly in the BM [12]. The fragments of γ2 chain are
specific for the laminin-5 [13]. Many studies have shown the
importance of laminin-5 in promoting tumor invasion through
interactions with several cell-surface receptors (including
α6β4 and α3β1 integrins, epidermal growth factor receptor,
and syndecan 1) and other basement membrane components
(including type VII collagen) and stimulation of cell migration
and/or invasion after BMdegradation. Based on its function, it
may support cancer cell invasion. Several immunohistochem-
ical studies have shown a positive correlation between
laminin-5 expression and tumor invasiveness [14–18].
Each of the laminin-5 constituent may be degraded into
smaller fragments. The laminin-5 can function as a motility
factor or as an adhesive factor, depending on the state of pro-
teolytic processing. One possibility is that plasmin can cleave
the α3 chain. This makes the laminin-5 an adhesive agent.
Another possibility is the cleavage of the γ2 chain by some
matrix metalloproteases (MT1-MMP, MMP-2) and the trig-
gering cell migration over laminin-5 [19].
The most common methods used for laminin-5 detection
and determination are immunohistochemistry and enzyme-
linked immunosorbent assay (ELISA), respectively [20].
Especially, expression of the laminin γ2 chain of tumors
was analyzed [21–23]. The most common methods used for
laminin-5 detection are time consuming, they are not quanti-
tative, and they require the use of the labels. The serum con-
centration of the N-terminal fragments of the γ2 chain by
immunoassay was measured [24].
As long as ELISA is practically the only available method
for laminin-5 determination, this method cannot be validated
by comparison with another method. This opportunity provides
the SPRI method developed in this work, which is label-free
and operates with entirely different methods of creation of the
analytical signal. Thus, ELISA and newly developed SPRI
methods can be used for mutual validation of the results.
The biosensor on the basis of laminin-5 interaction with
specific antibody was constructed. Next, the analytical param-
eters of SPRI biosensor were optimized and the ability of
biosensor for determination of laminin-5 in biological samples
was checked. Comparison with standard methods, ELISA,
and Western blot was performed.
Materials and methods
Recombinant human protein laminin-5 (M=approx. 900 kDa)
as standard (Abcam, USA, http://www.abcam.com/), rabbit
polyclonal antibody specific to human laminin-5 (M =
170 kDa) (Abcam, USA, http://www.abcam.com/), cysteamine
hydrochloride, N-ethyl-N ′-(3-dimethylaminopropyl)
carbodiimide (EDC), human albumin, glycoprotein GPIIb/IIIa
(Sigma, Steinheim, Germany, http://www.sigmaaldrich.com/
safc/facilities/steinheim-germany.html), N-hydroxysuccinimide
(NHS) (Aldrich, Munich, Germany, http://www.sigmaaldrich.
com/germany.html), and photopolymer Elpemer SD 2054 and
hydrophobic protective paint SD 2368 UV SG-DG (Peters,
Kempen, Germany, http://www.peters.de) were used as well as
absolute ethanol, acetic acid, hydrochloric acid, sodium
hydroxide, sodium chloride, sodium carbonate, sodium
phosphate, potassium phosphate, sodium acetate, potassium
chloride, magnesium chloride (POCh, Gliwice, Poland, http://
www.poch.com.pl/). HBS-ES buffer, pH=7.4 (0.01MHEPES,
0.15 M sodium chloride, 0.005 % Tween 20, 3 mM EDTA);
acetic buffer, pH=3.79–5.57; phosphate-buffered saline (PBS),
pH=7.4; phosphate buffer, pH=7.17–8.04; and carbonate buff-
er, pH=8.50–9.86 (BIOMED, Lublin, Poland, http://www.
biomed.lublin.pl) were used as received. ELISA kit for
laminin-5 determination (USCN Life Science, Inc., People’s
Republic of China, www.uscnk.com) was used. Aqueous
solutions were prepared with Milli-Q water (Simplicity®
Millipore). Argon N 5.0 with an Ar content ≥99.999 % was
used (Air Liquide Polska Sp. z o.o., Poland).
Chip preparation
Gold chips were manufactured as described in a previous pa-
per [6, 25]. The gold surface of the chip was coated with a
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photopolymer and printed hydrophobic paint as described in
the paper [26]. The chip has nine active sites with 12 free gold
surfaces each. The constructed system can simultaneously
measure the nine different samples. Twelve individual SPRI
signals for each sample can be obtained.
Atomic force microscopy measurements
The atomic force microscopy (AFM) measurements were per-
formed with a commercial Ntegra Prima scanning probe mi-
croscope (NT-MDT, Russia) using a tapping mode in ambient
conditions. Etalon probes (NT-MDT, Russia) with resonance
frequency around 140 kHz and curvature radius less than
10 nm were used.
Antibody immobilization
The gold chips with the previously prepared photopolymer
layers were rinsed with ethanol and water and dried under a
stream of nitrogen. They were then immersed in 20 mM of
cysteamine ethanolic solutions for at least 2 h. After this time,
the chips again were rinsed with ethanol and water and dried
under a stream of argon. Antibody solution in a PBS buffer,
activated with NHS (250 mM) and EDC (250 mM), was
placed on the amine-modified surface and incubated at
37 °C for 1 h [27]. Activation of the antibody was done by
introducing the 1:1 mixture of NHS and EDC in a carbonate
buffer solution (pH 8.5) into the antibody solution with vigor-
ous stirring for 5 min. The reaction between activated carbox-
ylic acid groups in the antibody and amines on the SPR chip
surface led to antibody immobilization by the covalent amide
bond. The bond valence is contingent on matching the antigen
binding site to an epitope of antibody. The prepared biosensor
was ready for the measurement of laminin-5 concentration.
The chip was used immediately.
AFM enables the observation of the surface of the biosen-
sor during its preparation. AFM measurements were per-
formed to confirm the creation of subsequent layers. All mea-
surements were done in ambient conditions. (AFM images of
the individual layers on the gold chip surface are presented in
the electronic supplementary material).
SPRI measurement general description
The exact manner of conducting SPRI measurements was
described in previous articles [28]. The schematic diagram
of the apparatus is given in Ref. [29]. Briefly, the measure-
ments were performed at a fixed angle of incident light and the
reflectivity was simultaneously measured across an entire chip
surface. The biosensor consists of 9 × 12 spots (Fig. 1a).
Measurements were performed across each single spot.
Potential differences in the number of pixels on each spot
and related measuring error are represented by the precision
of measurements. The images were taken after immobilization
of the antibody and then after interaction with laminin-5. The
contrast values obtained for all pixels across a particular sam-
ple single spot were integrated. Thus, the SPRI signal was
integrated over the single spot area.
A background correction was applied; i.e., some of the
places on the biosensor covered with PBS buffer were used
as controls. Non-specific binding was monitored by measur-
ing the signal SPRI in place on the chip without the receptor
(ligand). Minimization of the non-specific binding obtained
by preparing samples in PBS buffer (NaCl and KCl concen-
tration ∼200 mM) at pH 7.4 near the isoelectric point of the
protein. NIH ImageJ version 1.42 software was used to eval-
uate the SPRI images in 2D form and to convert numerical
signal to quantitative signal (AU). The analytical signal,
which is proportional to the mass changes caused by binding
of laminin, was obtained from subtraction between the signal
before and after interaction with laminin-5 for each spot sep-
arately. In this manner, 12 individual SPRI signals for each
sample were obtained (Fig. 1a).
Fig. 1 a Picture of chip (A photopolymer, B free gold surface, C
hydrophobic paint). b The SPR image of the chip obtained using a
CCD camera. c The schematic illustration of the sensor active part
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Preparation of biological samples
Plasma samples from healthy adult human donors from a
Blood Donor Center in Bialystok, Poland, were obtained.
Plasma samples from patients with bladder cancer were sup-
plied from the Department of Urology, Regional Hospital, in
Bialystok, Poland. Directly after collection, the samples were
stored at −20/−70 °C until use.
All the samples were provided after obtaining the consent
of the local Bioethical Commission for the study of the bio-
logical material collected.
Prepared plasma samples from healthy donors were diluted
1000-fold and those from bladder cancer patients (after pre-
liminary tests) 1000- or 10,000-fold with PBS. Next, 3 μL of
the sample dilution was applied to each active site of the
biosensor and allowed for 10 min. The volume of the sample
was determined by the size of the active place on the chip. The
optimum interaction time between antibody and laminin-5
was determined based on the earlier experiments, and it was
10 min. After interaction, the excess solution was removed by
rinsing the chip two times with HBS-ES buffer and five times
with distilled water. The SPRI measurement was performed.
The concentration was evaluated using a laminin-5 calibration
curve. Preparation of calibration curve is described in the
BResults and discussion^ section.
ELISA measurements
The determination of laminin-5 concentration in the blood
plasma was performed using a human laminin-5 enzyme-
linked immunoassay kit according to the manufacturer’s in-
structions. The calibration curve of the ELISA kit is within the
range of 15.6 to 1000 ng mL−1. The minimum detectable dose
of laminin-5 typically is less than 6.1 pg mL−1.
Statistical analysis
All results are given as the mean value ± confidence limits.
Student’s t test was used for statistical analysis. A p value of
≤0.05 was considered significant.
Results and discussion
Optimization of antibody concentration
Generally, the usefulness of biosensor is determined by the
relevant analytical parameters. The description of analytical
capabilities of biosensors includes four sets of parameters: (1)
calibration characteristics such as sensitivity, working and lin-
ear concentration range, detection, and quantitative determi-
nation limits; (2) selectivity and reliability; (3) response time;
and (4) reproducibility, stability, and lifetime.
The purpose of this investigation was to find the best con-
ditions for determination of laminin-5 concentration. The in-
vestigation was performed using the antibody in a concentra-
tion range of 0.1–10 ng mL−1 at a constant concentration of
laminin-5 (1 ng mL−1). For this purpose, nine antibody solu-
tions with concentrations 10, 8, 5, 4, 3, 2, 1.5, 1, 0.5, and
0.1 ng mL−1 were used. Briefly after chip preparation with
specific antibody and laminin-5 binding, the SPRI measure-
ment was performed. The results are given in Fig. 2. The
obtained curve is of the Langmuir isotherm type. SPRI signal
increased with an increase in antibody concentration from 0.1
to 5.0 ng mL−1. The plateau of the signal is observed for
antibody concentration above 5.0 ng mL−1 (see Fig. 2).
Influence of solution pH on interaction process
Physiological pH for antigen binding by antibody is 7.4 [30].
The influence of the laminin-5 solution pH on the SPRI signal
was studied within a pH range of 4.99–9.50. Biosensors were
prepared for measurements at the optimal concentration of
antibody (5.0 ng mL−1). Experiments were performed at con-
stant laminin-5 concentration (1 ng mL−1). The results are
shown in Fig. 3. Laminin-5 was bound to use specific anti-
body at a whole-investigation pH range. The maximum of the
SPRI signal was in the pH range of 7.0–7.5. Lower and higher
pH values resulted in significantly weaker SPRI signal. The
antibody solution pH of 7.4 was selected as an optimal value
for further testing.
Calibration curve
The response of the analytical SPRI signal for laminin-5 was
measured within a range of its concentration between 0.005
and 1.0 ng mL−1. For this purpose, the chip surface was
Fig. 2 Dependence of SPRI signal (arbitrary units) of antibody-laminin-
5 complex on antibody concentration. The laminin-5 concentration is
1 ng mL−1. The pH of laminin-5 solution was 7.4. Error bars are
calculated for 12 independent measurements for each concentration at a
95 % confidence level
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covered by a monolayer of cysteamine and a layer of
immobilized antibody with a concentration of 5 ng mL−1.
Laminin-5 solutions with different concentrations were put
on immobilized antibody for 10 min at pH 7.4. The obtained
calibration curve is shown in Fig. 4. That curve represents a
Langmuir isotherm type. The calibration of the biosensor gave
a linear response to a concentration of laminin-5 in the range
of 0.005–0.1 ng mL−1. This range is useful for analytical pur-
poses. The plateau of the curve corresponds to saturation of
the sensor active points.
The detection limit, calculated on 3 standard deviations
(SD) of the blank (PBS buffer) basis [31], is equal to
4 pg mL−1. Thus, the limit of quantification (10 SD of the
blank) is equal to 14 pg mL−1. These values are in an agree-
ment with the lowest results shown in Fig. 4. Thus, linear
range between 0.014 and 0.1 ng mL−1 can be used for deter-
mination of laminin-5 concentration.
Selectivity of the method
In order to demonstrate the selectivity of the biosensor, the
interferences of different compounds to the laminin-5 re-
sponse were examined. Human collagen type IV, albumin,
glycoprotein GPIIb/IIIa, and fibronectin as potential
interferents were used. Collagen type IV, fibronectin, and lam-
inin are components of basement membrane. Protein GPIIb/
IIIa and laminin belong to the same group of compounds,
glycoproteins. Therefore, they are proper proteins to test bio-
sensor specificity. Specificity of the interaction between anti-
body and laminin-5 was verified through treating a surface of
the chip with immobilized antibody layer (5.0 ng mL−1) by
mixtures of laminin-5 and potential interferents. Mixtures of
different ratios of laminin-5 (0.05 ng mL−1) and interfering
proteins were tested. The results are shown in Table 1. No
influence of albumin, glycoprotein GPIIb/IIIa, fibronectin,
and collage type IV on the results of determination of
laminin-5 concentration was found. Even at 1000-fold excess
of interferents used, SPRI sensors gave similar results. Thus,
high selectivity of the biosensor was confirmed.
Precision and recovery of the method
Precision of the developed method was tested under optimal
conditions, i.e., pH = 7.4 and antibody concentration of
5.0 ng mL−1. Experiments were performed for the solutions
with laminin-5 concentrat ions of 0.1, 0.05, and
0.014 ng mL−1. Three plates with 12 free gold points were
used for measuring each concentration. This gave 36 measur-
ing points. The results are shown in Table 2.
Fig. 4 Dependence of the SPRI signal (arbitrary units) on laminin-5
concentration. Linear ranges are on a separate sub-figure. The antibody
concentration is 5.0 ng mL−1. The pH of laminin-5 solution is 7.4. Error
bars are calculated for 12 independent measurements for each
concentration at a 95 % confidence level
Fig. 3 Dependence of SPRI signal (arbitrary units) of antibody-laminin-
5 complex on pH. The antibody concentration is 5.0 μg mL−1. The
laminin-5 concentration is 1.0 ng mL−1. Error bars are calculated for
12 independent measurements for each antibody solution pH point at a
95 % confidence level
Table 1 Influence of human albumin, glycoprotein IIb/IIIa, fibronectin,












Albumin 1:1 0.050 0.050 ± 0.003 100
1:100 0.052 ± 0.004 104
1:1000 0.054 ± 0.003 108
Glycoprotein
GPIIBb/IIIa
1:1 0.050 0.050 ± 0.005 100
1:100 0.054 ± 0.002 108
1:1000 0.055 ± 0.004 110
Fibronectin 1:1 0.050 0.050 ± 0.002 100
1:100 0.054 ± 0.007 108
1:1000 0.050 ± 0.002 100
Collagen type
IV
1:1 0.050 0.051 ± 0.002 102
1:100 0.055 ± 0.004 110
1:1000 0.055 ± 0.004 110
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The precision of average value, as well as confidence
limits, is acceptable. The recoveries of spikes are good, and
they appear in the range of 100–106 %.
Recovery of the developed method was checked by the
addition of standard solution of laminin-5 into nine different
samples of the human plasma. The final standard concentra-
tion in the sample was 50.0 ng mL−1. The results are shown in
Table 3. They are within the range of 98 to 106 %. The dif-
ferences of determined concentrations were not statistically
significant at p<0.05.
Determination of laminin-5 concentration in biological
samples
Samples of plasma from nine healthy adult donors and eight
patients with bladder cancer were analyzed for laminin-5 con-
centration using the developed method. The results of mea-
surements were evaluated on the basis of a calibration curve,
and they are given in Table 4.
In order to validate the developed method, comparative
determination of laminin-5 concentration in the same samples
by the commercial ELISA kit was performed (Table 4).
Generally, the comparison of results for separated samples
from healthy donors obtained by SPRI measurement and
ELISA indicates that they are close. For healthy subjects, the
mean value of laminin-5 concentrationwas established as 56.0
± 6.2 ng mL−1 with the SPRI biosensor and 51.4
±10.4 ng mL−1 with ELISA. The mean value of laminin con-
centration reported in the literature is 46.2±10.2 ng mL−1 [20].
The laminin-5 concentration in the blood plasma of bladder
cancer patients measured by both methods differed (mean
values from the SPRI biosensor method was 145.6 ± 26.5
and 112.1±17.6 ng mL−1 from ELISA). Also, all individual
plasma samples of cancer patients gave significantly higher
results measuredwith specific biosensor than by ELISA assay.
It could be supposed that those differences came from dispa-
rate principles of both methods. ELISA assay was based on
sandwich reaction of two different primary antibodies with
two separated parts of the same molecule of the detected an-
tigen. As a result, it needed longer polypeptide chain of inves-
tigated protein present in the biological sample than biosensor
used for SPRI measurement. That biosensor was prepared by
covering plate with one specific anti-laminin-5 antibody that
could bind as short antigen molecule, as it contained specific
epitope recognized by that used antibody. Blood plasma sam-
ples of cancer patients probably contained degradation prod-
ucts of laminin-5 with different lengths. About 23 % of them
were so short that they were detected with a biosensor only.
Even if those short fragments of laminin-5 were immobilized
on ELISA plate, they were too small to bind second primary
antibody of ELISA reagent. We tried to confirm that possibil-
ity by a Western immunoblot technique, as it was described
earlier [32]. Unfortunately, there were no any bands on nitro-
cellulose reacting with the same primary anti-laminin-5 anti-
body that were used for biosensor preparation. It indicated that
laminin-5 fragments detected with SPRI assay and ELISA test
had lower molecular mass than about 7 kDa, which could be
visualized by a Western blot technique.
At least three investigators found an increased laminin-5 loss
from the basement membrane of the urinary bladder [18, 33]
and its higher expression in bladder cancer [18, 34]. This might
lead to laminin-5 higher turnover with a simultaneous increase











SD Confidence limit (95 %)
(ng mL−1)
36 0.100 0.106 106 0.016 0.005
0.050 0.052 104 0.012 0.004
0.014 0.014 100 0.002 0.001
Table 3 Recoveries of laminin-5










1 46.7 ± 1.2 50.0 94.8 ± 1.8 98
2 51.1 ± 2.0 50.0 107.2 ± 2.2 106
3 51.9 ± 1.5 50.0 101.9 ± 2.1 100
4 52.9 ± 1.9 50.0 101.9 ± 1.5 99
5 62.6 ± 1.1 50.0 110.3 ± 1.7 98
6 60.2 ± 1.7 50.0 111.3 ± 1.7 101
7 53.3 ± 1.5 50.0 105.4 ± 2.1 102
8 57.7 ± 1.5 50.0 113.1 ± 1.4 105
9 37.1 ± 2.1 50.0 91.5 ± 1.2 105
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in concentration of its degradation products in the blood of
patients with urinary bladder cancer. Such significantly higher
content was found especially with the proposed SPRI method.
We supposed that the presented SPRI biosensor was an alter-
native to the standard methods for diagnosis of bladder cancer.
Conclusions
The SPRI biosensors for the determination of laminin-5 con-
centration have been developed. The biosensor was based on
the highly selective reaction between immobilized rabbit an-
tibody and laminin-5. This method allows measuring in real-
time interactions between biomolecules in a label-free manner
with high precision and specificity of the assay.
Compared with the ELISA assay, the newly developed
method proved to be a rapid, high-throughput, valuable, and
reproducible tool for detection of laminin-5.
The newly developed SPRI biosensor was used successful-
ly to determine laminin-5 concentration in serum. The study
shows the clear difference in concentration of laminin-5 in
healthy humans and patients with bladder cancer. Extensive
clinical studies using the newly developed method can give
rise to the use of laminin-5 as a potential cancer marker.
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